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Abbreviations: LM: lymphangioma, ECT: electrochemotherapy, ESOPE: European Standard 
Operating Procedures of Electrochemotherapy, MR: magnetic resonance
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The treatment of microcystic and combined lymphangiomas, especially in the head and neck 
region is still a challenge as they do not respond to conventional therapies, and their 
recurrence rate is high regardless of the treatment choice. The complete surgical resection is 
the best treatment for lymphangiomas, but due to the localization perioperative complications 
such as bleeding, neural damage or airway obstruction are common disadvantages of this 
method. Bleomycin based sclerotherapy is another common therapeutic approach, when the 
lymphocysts are aspirated and 25-50% of their volumes are replaced with sclerotisant drug. 
This is an effective treatment in those cases where the vessels are large enough for an 
intravascular or intracystic injection, but due to the small size of vessels and cysts, the 
microcystic and combined lymphangiomas are not suitable for sclerotherapy. Delivery of 
drugs for treating sclerosis to endothelial cells can be achieved by electroporation 
(electrochemotherapy) even for capillary malformations. A congenital, rapidly growing 
combined lymphangioma of the left cervicofacial region was treated with one session of 
bleomycin-based electrochemotherapy. Seven months after treatment, the growth-corrected 
target-volume decrease was 63% and the dislocation of the trachea and blood vessels 
previously observed had ceased. We suggest that bleomycin-based electrochemotherapy is a 
feasible alternative treatment option for capillary malformations.
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Lymphangiomas (LMs) are rare benign congenital malformations of lymphatic vessels. The 
incidence of LMs is reported to be from 1.2 to 2.8 per 1000 newborns.1 The most common 
localization of LMs is the cervicofacial region (95%), where vital structures can be 
compressed and infiltrated.1 Spontaneous regression is not probable for microcystic (0%) and 
combined types (2%) of LMs,2 and these types exhibit a high recurrence and complication 
rate such as hemorrhage (15%) or infection (27%), which can cause sudden enlargement, 
airway obstruction or death.2,3 Complete surgical resection is the best treatment for LMs, but 
in lesions infiltrating main blood vessels complete resection is not possible and it may result 
in serious complications.4-6 Bleomycin-based sclerotherapy is an effective treatment for LMs 
in cases where the vessels are large enough for an intravascular or intracystic injection. This 
therapy is not suitable for microcystic and combined LMs, due to the small size of the vessels 
and cysts. 
During reversible electroporation, the application of short-term, high-intensity electric pulses 
induces transient permeabilization of cell membranes, which enables the delivery of large 
hydrophilic molecules, such as bleomycin, to the cytosol. The combination of reversible 
electroporation and intratumoral bleomycin injection — referred to as bleomycin-based 
electrochemotherapy (ECT) or electrosclerotherapy — facilitates drug delivery to endothelial 
cells, resulting in sclerosis of the vessels and cyst, and, eventually, to the regression of the 
lesion. 
Representative case report
A congenital, rapidly growing, soft-tissue mass was observed on the left side of the neck and 
cheek of a full-term baby boy.  Magnetic resonance imaging demonstrated a prominent, 
heterogeneous, lobulated, multicystic mass. The trachea, left jugular vein and common carotid 
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artery were dislocated and compressed (Figure 2/ A-C). The T1-weighted contrast-enhanced 
MR images showed one large, high-lipid cyst (2x2 cm) at the level of the thyroid cartilage 
(Figure 2/A-B). The whole lesion volume was calculated by manual contouring and found to 
be 72.32 cm3. Due to the location of the tumor and to the small size of the vessels neither 
complete resection by surgery nor traditional bleomycin sclerotherapy was not suitable. The 
rapid growth of the tumor, which could increase the risk of airway obstruction, ischemia and 
feeding difficulties, our multidisciplinary board decided to perform ECT on the mixed LM.  
Transmucosal application of electrode application to avoid scarring was ruled out because of 
the high risk of mucosal swelling with consequential airway obstruction, considerable 
postoperative pain 7 and feeding problems.8 
Methods 
Treatment 
The first ECT session was performed when the child was 4 months old, according to the 
European Standard Operating Procedures of Electrochemotherapy (ESOPE) criteria.9,10 The 
treatment was carried out under general anesthesia using intratumoral injection of bleomycin 
(1000IU/ml). Since this is a first case of using ECT in a child with LM, no guideline exists 
about the bleomycin dosage. In LM-s the advised dose of bleomycin is 0.3-0.5 mg/kg for 
sclerotherapy. In our case 0.5 mg/kg was calculated and used for the treatment according to 
the weight of the baby and information from the drug database of the National Institute of 
Pharmacy and Nutrition12 (5.4 mg = 8100 IU, which is equivalent to 0.5 mg/kg). According to 
the ESOPE guideline the intratumoral bleomycin dose would have been 18000 IU based on 
the tumor volume9, namely a reduced dose of bleomycin was used in our case. The ESOPE 
guideline was developed for cancer treatment in adults. 9  It should be noted that Groselj et 
al.11 presented recently, that the antitumor effectiveness of electrochemotherapy is 
comparable when using standard or reduced bleomycin dose.  
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ECT was performed using a Cliniporator electric pulse generator (IGEA, s.r.l., Carpi, Italy) 
and row needle electrodes. 9,13 With every application eight consecutive pulses with duration 
of 100 µs and voltage-to-electrode distance ratio of 1000 V/cm were used for electroporation. 
During the first session of ECT 68 applications were performed to cover the whole lesion by 
the electric field. The average current was 5.27 A (2–14 A). Only one cyst (>2 cm) was 
aspirated, and the standard method (sclerotherapy) was used. During treatment, a biopsy was 
taken for histopathological examination, which was used to confirm the diagnosis of LM. 
Eight months after the first electrosclerotherapy a second session was performed with the 
same technique under intraoperative ultrasonography guidance. In this session the anterior 
triangle was treated, close to the main vessels. During the second session of ECT 74 
applications were performed, the average current was 5.55 A (2–13 A). Follow up included 
visits with the patient on a weekly basis in the first month and, after the first three months, 
every fourth week. During visits, the general state of health, mental and physical development 
of the child, size and density of the lesion and skin scars were examined. The patient’s parents 
gave their written informed consent prior to treatments. 
Therapeutic response evaluation
To follow the therapeutic response, imaging evaluations were performed before treatment, 
seven months after the first ECT session and five months after the second ECT session. The 
lesion volume in units of cm3 was manually determined from T2-weighted magnetic 
resonance (MR) slices. To evaluate objectively the therapeutic response, we corrected the 
absolute target volume reduction according to the growth of the baby. To measure the growth 
rate of the infant, the contralateral healthy parotid gland volume was determined by manual 
delineation in both time points.
Results 
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Despite prominent post-operative edema, the treatment was well tolerated by the patient and 
breast feeding was constant. In this case, no perioperative complications were experienced. 
One and two months after treatment, erysipelas evolved on the cheek and was resolved with 
antibiotic therapy. During subsequent visits, a constant decrease in the volume of the LM was 
observed. Five months after the first ECT, a distinct decrease in the tumor volume was 
revealed with physical examination (Figure 3). Seven months after the first ECT treatment, 
MR images indicated significant decrease of the multicystic mass and, most importantly, the 
restoration of the dislocated trachea and compressed vessels (Figure 2/D). The volume of the 
cystic mass was reduced to 48.09 cm3 from a 72.32 cm3. The absolute target volume decrease 
was 33.5%. The normal right parotid gland growth was from 3.40 cm3 to 6.08 cm3, therefore 
78.8% physiological growth rate of the parotid and the child was determined. Based on that 
calculation, 63% of growth corrected target volume decrease was achieved. To prevent the 
potential progression of the untreated area a second treatment was performed eight months 
after the first session of ECT. One year after the first session, the symmetry of the face was 
completely restored (Figure 3). After 17 months follow up no recurrence was observed. The 
mental and physical development of the child remained age-appropriate. Small skin scars and 
slight hyperpigmentation caused by the application of the electrodes remained visible on the 
treated area. 
Discussion
ECT is a commonly used local treatment for cutaneous metastases and primary skin cancer of 
any histology. 14-16 Several recently published reports describe treatment of benign vascular 
malformations with bleomycin-based ECT. McMorrow et al. reported a case in which a 
venous malformation was managed successfully with intratumoral delivery of bleomycin 
using ECT 17 and referred to the procedure as bleomycin-based electrosclerotherapy. 
Endothelial cells are valid targets for electroporation, especially for vessels with diameters 
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smaller than 5 mm.18 Therefore ECT, which is the combination of electroporation delivery of 
intratumoral bleomycin, facilitates drug delivery to endothelial cells even in microcystic 
cases, which leads to sclerosis of the vessels and cyst and regression of the tumor (Figure 1).19 
Moreover, electric pulses have an important immediate vascular effect which reduces blood 
flow transiently and prevents washout of the drug.18 In case of benign vascular lesions, the 
aim of ECT is to enhance the sclerosing effect.20 In our case, the growth-corrected target 
volume decrease was 63% after one session of ECT. This response considered to be very 
good, taking into account that the lesion was benign, and accordingly complete eradication 
was not necessary. Our major goal, to restore the position of the trachea and vessels, was 
achieved. The symmetry of the face was also restored, which is important for the social 
development of the child. 
Conclusion 
In our case, bleomycin-based ECT proved to be safe and effective in the treatment of a 
combined LM. Bleomycin-based ECT should be considered as a feasible alternative treatment 
option for microcystic and combined LMs for babies. Since this is the first use of bleomycin 
electrosclerotherapy in the management of capillary LMs in an infant, further studies are 
needed concerning the efficacy and safety of the method.
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Figure 1. Reversible electroporation. 
Delivery of electric pulses to target cells enhances bleomycin uptake into the cytosol by 
permeabilizing the cell membrane. After the pulses cease, the membrane reseals, trapping 
bleomycin molecules in cells, where their effect is exerted.
Figure 2. MR images
A. T1-weighted, contrast-enhanced coronal MR slice before the treatment shows 
dislocation of pharyngeal structures (red arrow). The midline of the head is indicated 
with a green broken line. One large, high-lipid cyst is indicated with a white arrow.
B. T1-weighted, contras-enhanced MR coronal view of the 3D reconstructed image 
before treatment shows the compressed and dislocated jugular vein and common 
carotid artery (red arrow). 
C. T2-weighted axial MR slice before treatment shows compression of surrounding 
structures and dislocation of the pharyngeal structures (red arrow). 
D. T2-weighted axial MR image 7 months after the treatment shows restored position of 
the pharynx .  
Figure 3. Photos of the patient
A. One week old: soft-tissue mass on the left side of the neck and cheek. 
B. Two months old: rapidly growing combined lymphangioma. 
C. Four months old, at the time of ECT. 
D. Nine months old, 5 months after ECT: significant decrease of the malformation.
E. Eleven months old, 7 months after ECT: further volume decrease.
F. Sixteen months old, 1 year after ECT: symmetry of the face is restored.
Video: T2 weighted STIR coronal image of first examination with before (red) and after 
(green) treatment target volumes in 3 dimensional view.
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Reversible electroporation. Delivery of electric pulses to target cells enhances bleomycin uptake into the 
cytosol by permeabilizing the cell membrane. After the pulses cease, the membrane reseals, trapping 
bleomycin molecules in cells, where their effect is exerted. 
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MR images: A. T1-weighted, contrast-enhanced coronal MR slice before the treatment shows dislocation of 
pharyngeal structures (red arrow). The midline of the head is indicated with a green broken line. One large, 
high-lipid cyst is indicated with a white arrow. B. T1-weighted, contras-enhanced MR coronal view of the 3D 
reconstructed image before treatment shows the compressed and dislocated jugular vein and common 
carotid artery (red arrow). C. T2-weighted axial MR slice before treatment shows compression of 
surrounding structures and dislocation of the pharyngeal structures (red arrow). D. T2-weighted axial MR 
image 7 months after the treatment shows restored position of the pharynx . 
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Photos of the patient: A. One week old: soft-tissue mass on the left side of the neck and cheek. B. Two 
months old: rapidly growing combined lymphangioma. C. Four months old, at the time of ECT. D. Nine 
months old, 5 months after ECT: significant decrease of the malformation. E. Eleven months old, 7 months 
after ECT: further volume decrease. F. Sixteen months old, 1 year after ECT: symmetry of the face is 
restored. 
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